Bristol-myers Squibb Compnay

Huji Turdi

R Michael Lawrence

Saleem Ahmad

Wei Meng

Pratik Devasthale

Jon J Hangeland

Guohua Zhao

Robert Paul Brigance

William R Ewing

Chongqing Sun

Yanting Huang

Dong Cheng

Wel Meng

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Aryl dihydropyridinones and piperidinone MGAT2 inhibitors

The present invention provides compounds of Formula (I):  or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Aryl dihydropyridinone and piperidinone MGAT2 inhibitors

Disclosed are triazolopyridine compounds of Formula (I), including pharmaceutically acceptable salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof. 

Triazolo compounds useful as DGAT1 inhibitors

Growing community of inventors

Yardley, PA, United States of America

Huji Turdi